ZENG Si-Yu
Department of Drug Clinical Trial, Second Peoples Hospital of Guangdong Province, Guangzhou, Guangdong 510317, ChinaHONG Chen-Liang
Institute of Drug and Pharmacology, University of South China, Hengyang, Hunan 421001, ChinaLAN Shu-Min
Department of Drug Clinical Trial, Second Peoples Hospital of Guangdong Province, Guangzhou, Guangdong 510317, ChinaLU Hui-Qin
Department of Drug Clinical Trial, Second Peoples Hospital of Guangdong Province, Guangzhou, Guangdong 510317, ChinaCHEN Yan
Department of Drug Clinical Trial, Second Peoples Hospital of Guangdong Province, Guangzhou, Guangdong 510317, ChinaYAN Qiu-Jiang
Department of Cardiothoracic Surgery, Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510000, ChinaQIN Xu-Ping
Institute of Drug and Pharmacology, University of South China, Hengyang, Hunan 421001, China1.Department of Drug Clinical Trial, Second People's Hospital of Guangdong Province, Guangzhou, Guangdong 510317, China;2.Institute of Drug and Pharmacology, University of South China, Hengyang, Hunan 421001, China;3.Department of Cardiothoracic Surgery, Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510000, China)
R363
ZENG Si-Yu, HONG Chen-Liang, LAN Shu-Min, LU Hui-Qin, CHEN Yan, YAN Qiu-Jiang, QIN Xu-Ping. ADAM17 regulates inhibitory effect of CGRP on angiotensin Ⅱ-induced proliferation of vascular smooth muscle cells[J]. Editorial Office of Chinese Journal of Arteriosclerosis,2017,25(8):778-782.
Copy